Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI
Xiaoxiao Zhao,1,* Li Song,1,* Ying Wang,1,* Jiannan Li,1 Jinying Zhou,1 Runzhen Chen,1 Chen Liu,1 Peng Zhou,1 Zhaoxue Sheng,1 Yi Chen,1 Hanjun Zhao,1 Hongbing Yan2 1Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical Col...
Enregistré dans:
Auteurs principaux: | Zhao X, Song L, Wang Y, Li J, Zhou J, Chen R, Liu C, Zhou P, Sheng Z, Chen Y, Zhao H, Yan H |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/dcd7a6b67a874af2b67e281f68bbbf4e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study
par: Patricia Muñoz Ramos, et autres
Publié: (2021) -
Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study
par: Jia Peng, et autres
Publié: (2021) -
Plasma Pentraxin-3 Combined with Plaque Characteristics Predict Cardiovascular Risk in ST-Segment Elevated Myocardial Infarction: An Optical Coherence Tomography Study
par: Wang Y, et autres
Publié: (2021) -
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
par: Hui Wang, et autres
Publié: (2017) -
Is pentraxin 3 level an effective biomarker in disease activity in patients with rheumatoid arthritis?
par: Ozlem Balbaloglu, et autres
Publié: (2019)